Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/1650
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCoutsouvelis, Johnen_US
dc.contributor.authorCorallo, Carmelaen_US
dc.contributor.authorSpencer, Andrewen_US
dc.contributor.authorAvery, Sharonen_US
dc.contributor.authorDooley, Michaelen_US
dc.contributor.authorKirkpatrick, Carlen_US
dc.date.accessioned2022-03-09T04:46:00Z-
dc.date.available2022-03-09T04:46:00Z-
dc.date.issued2022-
dc.identifier.citationCoutsouvelis J, Corallo C, Spencer A, Avery S, Dooley M, Kirkpatrick C. A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy. Crit Rev Oncol Hematol. 2022 Jan 28:103606. doi: 10.1016/j.critrevonc.2022.103606. Epub ahead of print. PMID: 35101586.en_US
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/1650-
dc.descriptionCairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Sharon Averyen_US
dc.description.abstractPalifermin, a recombinant keratinocyte growth factor promotes thickening of the mucosa, minimising severity of mucositis caused by chemotherapy and radiotherapy. To synthesise published literature on palifermin for the management of oral mucositis, in patients receiving chemotherapy and/or radiotherapy, aiming to ascertain recommendations for practice. Databases searched were Medline, Embase, IPA and CIANHL. A meta-analysis included randomised controlled trials (RCT) for palifermin compared to placebo or no palifermin, with the key data extracted being number of events of severe mucositis (defined by WHO criteria grade 3 or 4). The meta-analysis included 10 RCT. Patients were treated for solid and haematological malignancy. Analysis suggested benefit of palifermin decreasing the incidence of severe mucositis in solid tumours RR0.76 [95%CI 0.63-0.92;p = 0.004], haematological malignancy RR0.63 [95%CI 0.48-0.82;p = 0.0007] and overall RR0.69 [95%CI 0.59-0.81;p < 0.0001]. Palifermin reduces the incidence of severe mucositis up to 30 % in patients receiving treatment with chemotherapy and/or radiotherapy.en_US
dc.language.isoenen_US
dc.relation.ispartofCritical reviews in oncology/hematologyen_US
dc.subjectChemoradiotherapyen_US
dc.subjectHaematological malignancyen_US
dc.subjectOral mucositisen_US
dc.subjectPaliferminen_US
dc.subjectSolid tumouren_US
dc.subjectStem cell transplantationen_US
dc.titleA meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancyen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.critrevonc.2022.103606-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.openairetypeArticle-
item.grantfulltextnone-
item.fulltextNo Fulltext-
Appears in Sites:Cairns & Hinterland HHS Publications
Queensland Health Publications
Show simple item record

Page view(s)

100
checked on Apr 29, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.